Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICD Guidelines From ACC/AHA/NASPE Embrace MADIT-II Prophylactic Use

This article was originally published in The Gray Sheet

Executive Summary

ICDs should be implanted in heart attack victims whose left-ventricular ejection fraction is 30% or less one month after the event and three months post-revascularization, according to new practice guidelines issued jointly by ACC, AHA and NASPE
Advertisement

Related Content

Starts & Stops: Boston Scientific Starts, Stops, And Finishes TAVR Trials
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
CMS Critiques MADIT-II: “Inducible” Patients Should Have Been Excluded
Simple Back-Up Superior To Dual-Chamber Pacing For Certain ICD Patients
Sudden cardiac death prevention study
Cardiovascular Devices In Brief
Cardiologist Groups Guard Medicare ICD Payments From Physician Fee Cuts
Guidant MADIT II Trial Could Support Doubling Of ICD-Eligible Population
Guidant MADIT II Trial Could Support Doubling Of ICD-Eligible Population
Advertisement
UsernamePublicRestriction

Register

MT017221

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel